Cancer Immunology & Prevention

BOOST ANTIGEN-PRESENTATION COMBINED WITH CHECK-POINT INHIBITION

Down-regulation of (neo)antigens limits the efficacy of immune-checkpoint inhibitors. Interferon-g is a potent stimulator of MHC expression and antigen-presentation. Administration of systemic IFNg may boost checkpoint-inhibitors.

How will your solution make a difference

If toxicity can be managed for the proposed combination therapy, this treatment could result in expanding the response rate and duration of remission of treatment with immune check-point inhibitors for a variety of cancers.

What is your proposed solution

Interferon-g (IFNg) is the most potent inducer of expression of MHC I and II molecules and of antigen-processing and presentation. IFNg has been used systematically before (and toxicity, while present, can be managed). Thus we should design clinical trials for the combination of immune check-point inhibitors with systemic IFNg. One should also screen for novel small molecules that could enhance MHC and antigen expression

Voting

0 votes
Ideate
Idea No. 845